EUVIMEDEUVIMED entdecken
Übersichtsarbeit

FDA Experience on CAR T Cell Pharmacokinetics/Pharmacodynamics and Model‐Based Assessments

Million A Tegenge, Xiaofei Wang iD, Jiang Liu, Hao Zhu, Lola A Fashoyin-Aje iD

Clinical Pharmacology & Therapeutics · 2025-08 · 118 (2) · 324-330

DOI: 10.1002/cpt.3703 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical Pharmacology & Therapeutics, online erschienen am 04.05.2025. Verfasst von Million A Tegenge und 4 weiteren Autor:innen. Beteiligte Einrichtung: Office of Clinical Evaluation, Office of Therapeutic Products, Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver …. Hauptthemen laut MEDLINE: Immunotherapy, Adoptive, Receptors, Chimeric Antigen, Models, Biological, T-Lymphocytes. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 41 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chimeric antigen receptor T cell (CAR T) therapies are genetically modified T cells that are engineered to recognize specific cell surface antigens (e.g., CD19 or B cell maturation antigen (BCMA), expressed on B cells). The objective of this review is to describe FDA experience with assessing the pharmacokinetics (PK), pharmacodynamics (PD) and conducting model‐based analyses of FDA‐approved CAR T cell products. The seven currently approved CAR T cell products target CD19 or BCMA and have both flat dose and body‐weight‐based intravenous dosing. The PK (e.g., expansion and persistence) and PD (e.g., B‐cell aplasia, cytokine levels, and chemokine levels) data were an integral component of CAR T cell clinical pharmacology assessments. Model‐based assessments, including population PK and exposure–response analysis, were conducted to understand PK variability and identify intrinsic/extrinsic factors impacting safety and efficacy outcomes. Continued use of clinical pharmacology tools such as model‐based assessment to inform dose selection, dose optimization, and therapeutic individualization is integral to characterizing the effects of CAR T products.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunotherapy, AdoptiveReceptors, Chimeric AntigenModels, BiologicalT-LymphocytesReceptors, Antigen, T-CellHumansUnited StatesUnited States Food and Drug AdministrationAntigens, CD19B-Cell Maturation Antigen

Substanzen

Receptors, Chimeric AntigenAntigens, CD19B-Cell Maturation AntigenReceptors, Antigen, T-Cell

Autor:innen und Institutionen

  • Office of Clinical Evaluation, Office of Therapeutic Products, Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.
  • Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.

ORCID-Profile: Xiaofei Wang, Lola A Fashoyin-Aje

Zitieren

APA

Tegenge, M. A., Wang, X., Liu, J., Zhu, H., & Fashoyin-Aje, L. A. (2025). FDA Experience on CAR T Cell Pharmacokinetics/Pharmacodynamics and Model‐Based Assessments. Clinical Pharmacology & Therapeutics, 118(2), 324-330. https://doi.org/10.1002/cpt.3703

Vancouver

Tegenge MA, Wang X, Liu J, Zhu H, Fashoyin-Aje LA. FDA Experience on CAR T Cell Pharmacokinetics/Pharmacodynamics and Model‐Based Assessments. Clinical Pharmacology & Therapeutics. 2025;118(2):324-330. doi:10.1002/cpt.3703

BibTeX
@article{Tegenge2025,
  author = {Tegenge, Million A and Wang, Xiaofei and Liu, Jiang and Zhu, Hao and Fashoyin-Aje, Lola A},
  title = {FDA Experience on CAR T Cell Pharmacokinetics/Pharmacodynamics and Model‐Based Assessments},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2025},
  volume = {118},
  number = {2},
  pages = {324--330},
  doi = {10.1002/cpt.3703}
}
Kostenlos starten →